The primary objective of this study are: \- Describe the characteristics of all patients initiating sodium-glucose co-transporter-2 inhibitors (SGLT2i) and the modalities of prescriptions of these two drugs and the concomitant treatments. The secondary objectives are: * Assess the occurrence of atheromatous cardiovascular events (unstable angina, fatal and non-fatal Myocardial infarction (MI), Transient ischemic attack (TIA), fatal and non-fatal stroke), deaths from all causes, hospitalization for heart failure and hospitalization for end-stage renal disease as main and related diagnoses during the exposure to the studied treatment * Assess the occurrence of the main safety events (ketoacidosis, lower limb amputation and Fournier's gangrene) during the exposure to the studied treatment
Study Type
OBSERVATIONAL
Enrollment
547,150
Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
Boehringer Ingelheim
Paris, France
Baseline characteristic: Age
Time frame: up to 5 years
Baseline characteristic: Gender
Time frame: up to 5 years
Baseline characteristic: Region of residence
Time frame: up to 5 years
Baseline characteristic: History of diabetes (date of first Long Term Disease (LTD) status related to diabetes)
Time frame: up to 5 years
Baseline characteristic: Type of diabetes
Time frame: up to 5 years
Proportion of patients with a history of cardio-vascular events including heart failure hospitalizations and lower limb amputation, renal events, ketoacidosis, Fournier's gangrene over the two years before the index date (initiation of SGLT2i)
Time frame: up to 5 years
Incidence rate of acute cardiovascular atheromatous events during the exposure period following initiation of the SGLT2i
Time frame: up to 5 years
Time from drug initiation to first event of acute cardiovascular atheromatous events
Time frame: up to 5 years
Incidence rate of heart failure hospitalization during the exposure period following initiation of the SGLT2i
Time frame: up to 5 years
Time from drug initiation to first event of heart failure hospitalization
Time frame: up to 5 years
Incidence rate of deaths all cause during the exposure period following initiation of the SGLT2i
Time frame: up to 5 years
Time from drug initiation to death all cause
Time frame: up to 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.